NCT05380427View on ClinicalTrials.gov

A Phase I Clinical Trial Evaluating the Safety, Tolerability, and Pharmacokinetics of CU-40101 Liniment in Single and Multiple Doses in Adult Male Androgenic Alopecia Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

August 15, 2022

Primary Completion Date

November 15, 2023

Study Completion Date

February 22, 2024

Conditions
AGA
Interventions
DRUG

CU-40101

CU-40101，0.0025% CU-40101，0.005% CU-40101，0.01% CU-40101，0.02%

Trial Locations (1)

310052

The Second Affiliated Hospital Zhejiang University School of Medicine, Zhejiang

Sponsors
All Listed Sponsors
lead

Cutia Therapeutics（Wuxi）Co.,Ltd

INDUSTRY

NCT05380427 - A Phase I Clinical Trial Evaluating the Safety, Tolerability, and Pharmacokinetics of CU-40101 Liniment in Single and Multiple Doses in Adult Male Androgenic Alopecia Subjects | Biotech Hunter | Biotech Hunter